01.04.2016 08:00:00 CET
Company Announcement, Helsinki, 1 April 2016 at 9:00 am
Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients with the use of non-invasive brain stimulation, today announces the appointment of John Liedtky as VP of Commercialization, General Manager US, effective from 1 April 2016. Mr. Liedtky will also join Nexstim Management Team and will be responsible of Pre-Surgical Mapping business and commercial development of therapeutic indications. At the same time, Nexstim announces the planned retirement of John Hardin, Vice President, Pre-surgical Mapping from Nexstim's Management Team on 6 May 2016.
John Liedtky is a global healthcare executive with extensive experience in the medical device and equipment space, having previously held Global Marketing Vice Presidency Roles at DJO Global, COVIDIEN and BREG Inc. John Liedtky is an expert in leading cross-functional teams through the complete product life-cycle, from upstream development to strategic downstream marketing and sales management tactics, and has experience with a breadth of technologies and business models in both the US and Internationally.
Nexstim's CEO, Janne Huhtala, said: "We welcome John Liedtky to the team as we continue to grow in the important US market, both in PSM and therapeutic indications. We thank John Hardin for the significant contribution that he has made to Nexstim and are grateful for all that he has done for pre-surgical mapping, our NBS system and the Company. We wholeheartedly wish him well for the future."
Janne Huhtala, CEO
For further information please visit www.nexstim.com or contact:
Nexstim +358 (0)40 8615046
Janne Huhtala, Chief Executive Officer firstname.lastname@example.org
UB Securities Ltd (Certified Adviser) +358 (0)9 2538 0246
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Laura Thornton email@example.com
About Nexstim Plc
Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBTŪ). Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com